SL Science Holding Limited Ordinary Shares (SLBT) - Net Assets
Based on the latest financial reports, SL Science Holding Limited Ordinary Shares (SLBT) has net assets worth $2.28 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($2.82 Million) and total liabilities ($533.28K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore SL Science Holding Limited Ordinary Shar assets under control for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $2.28 Million |
| % of Total Assets | 81.07% |
| Annual Growth Rate | -20.05% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 60.18 |
SL Science Holding Limited Ordinary Shares - Net Assets Trend (2023–2025)
This chart illustrates how SL Science Holding Limited Ordinary Shares's net assets have evolved over time, based on quarterly financial data. Check how tangible is SL Science Holding Limited Ordinary Shar's equity to evaluate the tangible quality of the company's equity base.
Annual Net Assets for SL Science Holding Limited Ordinary Shares (2023–2025)
The table below shows the annual net assets of SL Science Holding Limited Ordinary Shares from 2023 to 2025. For live valuation and market cap data, see SL Science Holding Limited Ordinary Shar market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $2.28 Million | -60.12% |
| 2024-12-31 | $5.73 Million | +60.25% |
| 2023-12-31 | $3.57 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to SL Science Holding Limited Ordinary Shares's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 548437800.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $367.50K | 16.09% |
| Other Comprehensive Income | $469.44K | 20.55% |
| Other Components | $6.93 Million | 303.49% |
| Total Equity | $2.28 Million | 100.00% |
SL Science Holding Limited Ordinary Shares Competitors by Market Cap
The table below lists competitors of SL Science Holding Limited Ordinary Shares ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shanghai Bairun Flavor & Fragrance Co Ltd
SHE:002568
|
$2.65 Billion |
|
Aerospace CH UAV Co Ltd
SHE:002389
|
$2.65 Billion |
|
Auras Technology Co Ltd
TWO:3324
|
$2.65 Billion |
|
Himax Technologies Inc
NASDAQ:HIMX
|
$2.66 Billion |
|
Netweb Technologies India Limited
NSE:NETWEB
|
$2.65 Billion |
|
Suzhou Hengmingda Electronic Technology Co Ltd
SHE:002947
|
$2.65 Billion |
|
IRB Infrastructure Developers Limited
NSE:IRB
|
$2.65 Billion |
|
Home Product Center Public Company Limited
BK:HMPRO
|
$2.65 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in SL Science Holding Limited Ordinary Shares's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 5,727,053 to 2,283,903, a change of -3,443,150 (-60.1%).
- Net loss of 3,819,818 reduced equity.
- Other comprehensive income increased equity by 240,971.
- Other factors increased equity by 135,697.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-3.82 Million | -167.25% |
| Other Comprehensive Income | $240.97K | +10.55% |
| Other Changes | $135.70K | +5.94% |
| Total Change | $- | -60.12% |
Book Value vs Market Value Analysis
This analysis compares SL Science Holding Limited Ordinary Shares's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1161.34x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 742.17x to 1161.34x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2023-12-31 | $0.01 | $4.73 | x |
| 2024-12-31 | $0.01 | $4.73 | x |
| 2025-12-31 | $0.00 | $4.73 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently SL Science Holding Limited Ordinary Shares utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -167.25%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -173.85%
- • Asset Turnover: 0.78x
- • Equity Multiplier: 1.23x
- Recent ROE (-167.25%) is below the historical average (-58.96%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2023 | 11.17% | 45.40% | 0.21x | 1.19x | $41.65K |
| 2024 | -20.80% | -35.42% | 0.57x | 1.04x | $-1.76 Million |
| 2025 | -167.25% | -173.85% | 0.78x | 1.23x | $-4.05 Million |
Industry Comparison
This section compares SL Science Holding Limited Ordinary Shares's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $147,081,944
- Average return on equity (ROE) among peers: -21.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| SL Science Holding Limited Ordinary Shares (SLBT) | $2.28 Million | 11.17% | 0.23x | $2.65 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $165.48 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-17.08 Million | 0.00% | 0.00x | $335.61 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $181.82 Million | -56.28% | 0.31x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $-41.16 Million | 0.00% | 0.00x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $35.44 Million | -26.32% | 0.18x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $35.27K | -72.00% | 1.50x | $39.26 Million |
| Abivax SA American Depositary Shares (ABVX) | $71.77 Million | -22.23% | 0.06x | $12.08 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $479.08 Million | -51.18% | 0.13x | $3.66 Billion |
About SL Science Holding Limited Ordinary Shares
SL Science Holding Limited manufactures cosmetic skin care and scalp care products. The company's products include SL bio's milk-derived exosome essence, SL bio's tangerine-derived extract, and the MilkExo concentrate series. It also offers research services in armed T-cells, gamma delta T- cells, citrus reticulata (tangerine) extract, and milk-derived exosomes. SL Science Holding Limited was for… Read more